iclepertin (BI 425809)对精神分裂症患者认知功能的影响

IF 0.6 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2022-07-19 DOI:10.2217/fnl-2022-0008

K. Nakagome

引用次数: 0

摘要

ClinicalTrials.gov NCT编号：NCT02832037

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia

ClinicalTrials.gov NCT number: NCT02832037

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.